Holen Sie sich die Stockscreener-App
3.3297
0.18%
-0.0103
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$3.34
Offen:
$3.34
24-Stunden-Volumen:
1.87M
Relative Volume:
0.42
Marktkapitalisierung:
$433.90M
Einnahmen:
$41,000
Nettoeinkommen (Verlust:
$-88.09M
KGV:
-3.2792
EPS:
-1.0154
Netto-Cashflow:
$-67.55M
1W Leistung:
+15.76%
1M Leistung:
-5.82%
6M Leistung:
-16.86%
1J Leistung:
-21.37%
1-Tages-Spanne:
$3.30
$3.48
1-Wochen-Bereich:
$2.95
$3.48
52-Wochen-Spanne:
$2.87
$7.73
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.335 | 434.55M | 41,000 | -88.09M | -67.55M | -1.0154 |
VRTX
Vertex Pharmaceuticals Inc
|
433.58 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.40 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.05 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.89 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.74 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Eingeleitet | Truist | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Sell |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-24 | Eingeleitet | Goldman | Neutral |
| 2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-11 | Eingeleitet | Guggenheim | Buy |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-11-12 | Bestätigt | B. Riley Securities | Buy |
| 2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
| 2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
| 2019-07-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Altimmune, Inc. (ALT) gains analyst support as pemvidutide advances - MSN
Altimmune Inc.’s New Price Target Ignites Investor Interest - timothysykes.com
Altimmune Stock Outlook Brightens as Analysts Raise Price Targets - StocksToTrade
Altimmune’s Stock Target Raised as MASH Program Gains Momentum - timothysykes.com
Gitlab, Altimmune, Cheniere, Pacific Biosciences, Hercules Shock Wall Street - tipranks.com
Altimmune’s Price Surge After H.C. Wainwright Strengthens Outlook - StocksToTrade
ALT stock has nearly halved in the past year, so why does Wall Street see almost 500% upside? - MSN
Altimmune Inc Phase 2b Topline 48-Week Data Conference Call Transcript - gurufocus.com
Q3 2025 Altimmune Inc Earnings Call Transcript - gurufocus.com
ALT Stock Price, Quote & Chart | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Lilly gains after FDA approves weight-loss pill, sizing down investor doubts - Sahm
Insider Buying: Gregory Weaver Acquires 10,000 Shares of Altimmune Inc (ALT) - GuruFocus
Altimmune (ALT) CFO adds 10,000 shares in open-market stock purchase - Stock Titan
Altimmune (NASDAQ: ALT) CEO adds 15,000 shares in open-market buy - Stock Titan
Insider Buying: Gregory Weaver Acquires 10,000 Shares of Altimmu - gurufocus.com
Options Flow: Will Altimmune Inc announce a stock split2026 Market WrapUp & Real-Time Buy Signal Alerts - baoquankhu1.vn
Top 10 stocks under $5 that could triple - MSN
ALT (Altimmune) Common Stock : $0.01 Mil (As of Dec. 2025) - gurufocus.com
ALT (Altimmune) Shares Outstanding (Diluted Average) : 105.82 Mil (As of Dec. 2025) - GuruFocus
ALT (Altimmune) 5-Year RORE % : -16.56% (As of Dec. 2025) - GuruFocus
Pullback Watch: Can Altimmune Inc disrupt its industrySell Signal & Low Drawdown Investment Strategies - baoquankhu1.vn
Altimmune Inc. (ALT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ALT (Altimmune) FCF Yield % : -17.19 (As of Mar. 27, 2026) - GuruFocus
ALT (Altimmune) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2025) - GuruFocus
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
Jefferies reiterates Buy on Altimmune stock, keeps $28 target - Investing.com UK
Jefferies reiterates Buy on Altimmune stock, keeps $28 target By Investing.com - Investing.com India
Vanguard subsidiaries disaggregate holdings; Altimmune (NASDAQ: ALT) showing 0 shares - Stock Titan
ALT (Altimmune) EPS without NRI : $-1.01 (TTM As of Dec. 2025) - GuruFocus
Altimmune appoints Luis Sanay as vice president of investor relations to strengthen financial communications - Traders Union
ALT Pemvidutide Uncovered: How It Stands Apart in MASH - Bitget
Altimmune Stock: Balanced Perspective With Major Catalysts Expected in 2026 - Bitget
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms - Yahoo Finance Singapore
Altimmune Stock: Neutral Outlook With Big 2026 Catalysts - TradingView
ALT Pemvidutide Explained: What Makes It Different in MASH - Yahoo Finance
Altimmune a new buy at Truist on pemvidutide promise - MSN
HC Wainwright bullish on Altimmune (ALT) amid growing focus on treatments for metabolic and liver diseases - MSN
H.C. Wainwright Bullish on Altimmune (ALT) Amid Growing Focus on Treatments for Metabolic and Liver Diseases - Insider Monkey
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning - Benzinga
ALT SEC FilingsAltimmune 10-K, 10-Q, 8-K Forms - Stock Titan
Altimmune outlines 1,800-patient phase III MASH trial and signals cash runway into 2028 as pemvidutide advances - MSN
Growth Value: Can Altimmune Inc stock outperform in a bear marketWeekly Market Report & Consistent Income Trade Recommendations - baoquankhu1.vn
Viking Therapeutics: Phase 3 Obesity Data Feels Like A Coin Toss (Rating Downgrade) (VKTX) - Seeking Alpha
ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns - MSN
Truist initiates Altimmune stock coverage with buy rating on drug potential - Investing.com Australia
Altimmune (ALT) Gains Buy Rating with Promising MASH Treatment - GuruFocus
Altimmune (NASDAQ:ALT) Now Covered by Analysts at Truist Financial - MarketBeat
What is HC Wainwright's Estimate for Altimmune Q1 Earnings? - MarketBeat
Altimmune (FRA:3G0) NonCurrent Deferred Revenue : €0.14 Mil (As of Dec. 2025) - GuruFocus
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Altimmune Inc-Aktie (ALT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Durso Jerome Benedict | President and CEO |
Apr 01 '26 |
Buy |
3.14 |
15,000 |
47,100 |
47,500 |
| WEAVER GREGORY L | Chief Financial Officer |
Mar 06 '26 |
Buy |
3.54 |
5,000 |
17,700 |
28,078 |
| Durso Jerome Benedict | President and CEO |
Mar 06 '26 |
Buy |
3.54 |
20,000 |
70,790 |
32,500 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '26 |
Option Exercise |
0.00 |
7,775 |
0 |
115,153 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '26 |
Option Exercise |
0.00 |
9,275 |
0 |
104,670 |
| Garg Vipin K | Director |
Jan 30 '26 |
Option Exercise |
0.00 |
26,775 |
0 |
429,225 |
| Jordt Raymond M | Chief Business Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
69,765 |
| Garg Vipin K | Director |
Jan 27 '26 |
Option Exercise |
0.00 |
41,200 |
0 |
420,348 |
| Roberts M Scot | Chief Scientific Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
100,143 |
| Jordt Raymond M | Chief Business Officer |
Jan 25 '26 |
Option Exercise |
0.00 |
14,600 |
0 |
57,770 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):